Mölndal, Sweden

Eva-Lotte Lindstedt Alstermark


Average Co-Inventor Count = 3.5

ph-index = 3

Forward Citations = 13(Granted Patents)


Location History:

  • Göteborg, SE (2003)
  • Mölndal, SE (2002 - 2008)
  • Höludal, SE (2009)

Company Filing History:


Years Active: 2002-2009

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Eva-Lotte Lindstedt Alstermark: Innovator in Therapeutic Agents

Introduction

Eva-Lotte Lindstedt Alstermark is a prominent inventor based in Mölndal, Sweden. She has made significant contributions to the field of therapeutic agents, holding a total of 6 patents. Her work focuses on developing compounds that address clinical conditions, particularly lipid disorders.

Latest Patents

Among her latest patents, one invention provides a compound of formula I, detailing processes for preparing such compounds. These compounds are useful in treating clinical conditions, including lipid disorders (dyslipidemias), whether or not associated with insulin resistance. Another patent presents the S enantiomer of a compound of formula I, where R represents chloro, trifluoromethyl, or trifluoromethoxy. This patent also discusses the utility of these compounds in treating lipid disorders and includes methods for their therapeutic use and pharmaceutical compositions containing them.

Career Highlights

Eva-Lotte is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. Her work at AstraZeneca has allowed her to contribute to innovative solutions in the healthcare sector.

Collaborations

She has collaborated with notable coworkers, including Lanna Li and Kjell Andersson, enhancing the research and development efforts within her team.

Conclusion

Eva-Lotte Lindstedt Alstermark's contributions to therapeutic agents demonstrate her commitment to advancing medical science. Her innovative patents and collaborations reflect her significant role in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…